Transaction Information
Capital Raise
SEK 60 million
April 2024
Financial Adviser
About Scandion Oncology
Scandion is a clinical-stage biotech company using an innovative drug efflux pump inhibition technique with biomodulation capabilities on ABCG2 and UGT1A1 targets to revert drug resistance. Drug resistance remains a massive problem in cancer treatment and in the development of new medicines. Scandion’s lead compound SCO-101 is currently studying metastatic colorectal cancer (mCRC) in its Phase 2 CORIST trial, while the PANTAX Phase 1 program is developing SCO-101 for pancreatic cancer. Scandion is based in Copenhagen and is listed on Nasdaq First North Growth Market Sweden (ticker: SCOL).
The case
90% of cancer deaths are attributable to cancer drug resistance. Scandion Oncology, overcoming cancer drug resistance - improving lives for cancer patients and their families.
Website: https://scandiononcology.com/